Scintigra develops diagnostic radiopharmaceuticals for positron emission tomography (PET) and Single Photon Emission Computerized Tomography (SPECT) that are capable of enhancing the management of patients with cancer, Alzheimer's disease, Parkinson's disease and heart disease.  Based on the work of Dr. Mark Goodman at Emory University, the company has developed proprietary compounds and has demonstrated their potential to detect the earliest stages of disease in preclinical studies.